000142097 001__ 142097
000142097 005__ 20240229105143.0
000142097 0247_ $$2doi$$a10.18632/oncotarget.25032
000142097 0247_ $$2pmid$$apmid:29854288
000142097 0247_ $$2pmc$$apmc:PMC5976474
000142097 037__ $$aDKFZ-2018-02327
000142097 041__ $$aeng
000142097 082__ $$a610
000142097 1001_ $$aNiland, Stephan$$b0
000142097 245__ $$aRhodocetin-αβ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models.
000142097 260__ $$a[S.l.]$$bImpact Journals LLC$$c2018
000142097 3367_ $$2DRIVER$$aarticle
000142097 3367_ $$2DataCite$$aOutput Types/Journal article
000142097 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683544920_26275
000142097 3367_ $$2BibTeX$$aARTICLE
000142097 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142097 3367_ $$00$$2EndNote$$aJournal Article
000142097 520__ $$aThe tumor vasculature differs from normal blood vessels in morphology, composition and stability. Here, we describe a novel tumor vessel-disrupting mechanism. In an HT1080/mouse xenograft tumor model rhodocetin-αβ was highly effective in disrupting the tumor endothelial barrier. Mechanistically, rhodocetin-αβ triggered MET signaling via neuropilin-1. As both neuropilin-1 and MET were only lumen-exposed in a subset of abnormal tumor vessels, but not in normal vessels, the prime target of rhodocetin-αβ were these abnormal tumor vessels. Consequently, cells lining such tumor vessels became increasingly motile which compromised the vessel wall tightness. After this initial leakage, rhodocetin-αβ could leave the bloodstream and reach the as yet inaccessible neuropilin-1 on the basolateral side of endothelial cells and thus disrupt nearby vessels. Due to the specific neuropilin-1/MET co-distribution on cells lining such abnormal tumor vessels in contrast to normal endothelial cells, rhodocetin-αβ formed the necessary trimeric signaling complex of rhodocetin-αβ-MET-neuropilin-1 only in these abnormal tumor vessels. This selective attack of tumor vessels, sparing endothelial cell-lined vessels of normal tissues, suggests that the neuropilin-1-MET signaling axis may be a promising drugable target for anti-tumor therapy, and that rhodocetin-αβ may serve as a lead structure to develop novel anti-tumor drugs that target such vessels.
000142097 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000142097 588__ $$aDataset connected to CrossRef, PubMed,
000142097 7001_ $$0P:(DE-He78)30816ab8532422ad8d4a8af55bc0d24b$$aKomljenovic, Dorde$$b1
000142097 7001_ $$aMacas, Jadranka$$b2
000142097 7001_ $$aBracht, Thilo$$b3
000142097 7001_ $$0P:(DE-HGF)0$$aBäuerle, Tobias$$b4
000142097 7001_ $$aLiebner, Stefan$$b5
000142097 7001_ $$aEble, Johannes A$$b6
000142097 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.25032$$gVol. 9, no. 32$$n32$$p22406- 22422$$tOncoTarget$$v9$$x1949-2553$$y2018
000142097 909CO $$ooai:inrepo02.dkfz.de:142097$$pVDB
000142097 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)30816ab8532422ad8d4a8af55bc0d24b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142097 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142097 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000142097 9141_ $$y2018
000142097 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142097 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142097 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142097 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142097 9201_ $$0I:(DE-He78)E020-20160331$$kE020$$lE020 Med. Physik in der Radiologie$$x0
000142097 980__ $$ajournal
000142097 980__ $$aVDB
000142097 980__ $$aI:(DE-He78)E020-20160331
000142097 980__ $$aUNRESTRICTED